COVID-19 — Vaccine Adverse Events: VAERS, Underreporting, and Pharmacovigilance
COVID-19 — Vaccine Adverse Events: VAERS, Underreporting, and Pharmacovigilance
[edit | edit source]Overview
[edit | edit source]Understanding vaccine adverse event data requires understanding the surveillance systems that collect it. The Vaccine Adverse Event Reporting System (VAERS)*** — jointly administered by the CDC and FDA — is the primary U.S. post-authorization vaccine safety surveillance database. Its data has been both misused in public discourse (treating every report as a confirmed vaccine death) and defensively minimized (treating every safety signal as noise). An accurate understanding requires knowing what VAERS is designed to do, what its limitations are, and how it interacts with complementary surveillance systems.
What VAERS Is
[edit | edit source]VAERS is a passive surveillance system*** — it collects reports of adverse events following vaccination from healthcare providers, patients, vaccine manufacturers, and the public. Anyone can file a VAERS report. Key characteristics:
- A VAERS report is not*** a confirmed vaccine injury; it is a signal to investigate***
- Reports include all adverse events occurring after vaccination, regardless of whether the vaccine caused them
- The system is intentionally inclusive to maximize signal detection; it is designed to miss few events, not to avoid false positives
- VAERS data is used by the CDC and FDA to identify signals that warrant further investigation through active surveillance systems
What VAERS Is Not
[edit | edit source]The most common misuse of VAERS data — prominent in both pro- and anti-vaccine discourse — involves treating VAERS reports as confirmed vaccine injuries or confirmed vaccine deaths. The CDC explicitly states: "A report to VAERS generally cannot be used to determine if a vaccine caused or contributed to an adverse event or illness."*** VAERS report counts should not be compared to other cause-of-death statistics without adjustment.
Underreporting: A Real Limitation
[edit | edit source]Conversely, VAERS is also subject to significant underreporting. Studies have estimated that only 1–10% of actual vaccine adverse events are reported to VAERS, with severe events reported at higher rates than mild ones. This underreporting means that VAERS data underestimates the absolute number of adverse events. Regulatory agencies use VAERS alongside active surveillance (the Vaccine Safety Datalink; the Clinical Immunization Safety Assessment Project) that actively seek out adverse events in defined populations.
Complementary Surveillance Systems
[edit | edit source]| System | Type | Function |
|---|---|---|
| VAERS | Passive spontaneous reporting | Signal detection; hypothesis generation |
| Vaccine Safety Datalink (VSD) | Active surveillance in defined HMO populations | Quantify signals identified in VAERS; calculate attributable rates |
| Clinical Immunization Safety Assessment (CISA) | Expert clinical evaluation | Assess complex individual cases |
| Biologics Effectiveness and Safety (BEST) Initiative | Active surveillance | Complement VSD with additional data sources |
| UK Yellow Card Scheme | Passive (equivalent to VAERS) | UK signal detection |
| EudraVigilance (EU/EEA) | Passive | European signal detection |
| WHO VigiBase | Global passive surveillance | Aggregate international reports |
COVID-19 and VAERS Volume
[edit | edit source]The COVID-19 vaccination campaign produced an unprecedented volume of VAERS reports — not because COVID-19 vaccines were uniquely dangerous, but because:
- An unprecedented number of doses were administered in a short period
- Heightened awareness of the new vaccines led to higher-than-usual reporting rates
- Passive reporting was encouraged, including from the general public
- Some reporting was coordinated by advocacy groups, potentially inflating counts for specific events
The elevated VAERS volume requires even more careful interpretation than usual — per-dose rates, not absolute counts, are the appropriate comparative metric.
